EP1945223A4 - Compositions de cefquinome et procédés d'utilisation de celles-ci - Google Patents

Compositions de cefquinome et procédés d'utilisation de celles-ci

Info

Publication number
EP1945223A4
EP1945223A4 EP06851366A EP06851366A EP1945223A4 EP 1945223 A4 EP1945223 A4 EP 1945223A4 EP 06851366 A EP06851366 A EP 06851366A EP 06851366 A EP06851366 A EP 06851366A EP 1945223 A4 EP1945223 A4 EP 1945223A4
Authority
EP
European Patent Office
Prior art keywords
compositions
cefquinome
methods
kits
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06851366A
Other languages
German (de)
English (en)
Other versions
EP1945223A2 (fr
EP1945223B1 (fr
Inventor
Susan M Cady
Carole Barbot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Priority to PL06851366T priority Critical patent/PL1945223T3/pl
Priority to EP06851366A priority patent/EP1945223B1/fr
Publication of EP1945223A2 publication Critical patent/EP1945223A2/fr
Publication of EP1945223A4 publication Critical patent/EP1945223A4/fr
Application granted granted Critical
Publication of EP1945223B1 publication Critical patent/EP1945223B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP06851366A 2005-10-29 2006-10-27 Compositions de cefquinome et procédés d'utilisation de celles-ci Active EP1945223B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL06851366T PL1945223T3 (pl) 2005-10-29 2006-10-27 Kompozycje cefchinomu i sposoby ich stosowania
EP06851366A EP1945223B1 (fr) 2005-10-29 2006-10-27 Compositions de cefquinome et procédés d'utilisation de celles-ci

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73146305P 2005-10-29 2005-10-29
EP06111029 2006-03-13
EP06851366A EP1945223B1 (fr) 2005-10-29 2006-10-27 Compositions de cefquinome et procédés d'utilisation de celles-ci
PCT/US2006/041952 WO2007145656A2 (fr) 2005-10-29 2006-10-27 Compositions de cefquinome et procédés d'utilisation de celles-ci

Publications (3)

Publication Number Publication Date
EP1945223A2 EP1945223A2 (fr) 2008-07-23
EP1945223A4 true EP1945223A4 (fr) 2009-11-25
EP1945223B1 EP1945223B1 (fr) 2010-07-07

Family

ID=37728210

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06851366A Active EP1945223B1 (fr) 2005-10-29 2006-10-27 Compositions de cefquinome et procédés d'utilisation de celles-ci

Country Status (9)

Country Link
US (1) US20080318919A1 (fr)
EP (1) EP1945223B1 (fr)
JP (1) JP5322649B2 (fr)
AT (1) ATE472996T1 (fr)
CA (1) CA2626273C (fr)
ES (1) ES2346573T3 (fr)
PL (1) PL1945223T3 (fr)
PT (1) PT1945223E (fr)
WO (1) WO2007145656A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077320A1 (es) * 2009-07-20 2011-08-17 Intervet Int Bv Metodo para la preparacion de particulas de cefquinoma y formulaciones farmaceuticas que las comprenden.
EP2705044A1 (fr) 2011-05-02 2014-03-12 Zoetis Llc Nouvelles céphalosporines utiles en tant qu'agents antibactériens
CN105079000B (zh) * 2015-09-22 2018-07-06 佛山市南海东方澳龙制药有限公司 一种组合物及其应用、制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380741A (en) * 1971-02-05 1975-01-15 Squibb & Sons Inc Antibiotic compositions and their preparation
EP0388510A1 (fr) * 1989-03-18 1990-09-26 Hoechst Aktiengesellschaft Compositions pharmaceutiques et leur utilisation pour la prophylaxie ou le traitement des maladies infectieuses bactériennes
EP0711774A1 (fr) * 1994-11-10 1996-05-15 Hoechst Aktiengesellschaft Sels d'addition cristallin de céphem et procédé pour leur préparation
US20030186957A1 (en) * 2001-11-30 2003-10-02 Blanchflower Simon E. Methods of treatment and formulations of cephalosporin
WO2004054538A1 (fr) * 2002-12-16 2004-07-01 Akzo Nobel N.V. Traitement de la mastite
US6911411B2 (en) * 2001-11-21 2005-06-28 Polyfuel, Inc. Catalyst agglomerates for membrane electrode assemblies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3706020A1 (de) * 1987-02-25 1988-09-08 Hoechst Ag Kristallisierte cephem-saeureadditionssalze und verfahren zu ihrer herstellung
JPH0662419B2 (ja) * 1987-12-04 1994-08-17 武田薬品工業株式会社 抗生物質組成物
JP4700291B2 (ja) * 2003-04-28 2011-06-15 武田薬品工業株式会社 注射用組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380741A (en) * 1971-02-05 1975-01-15 Squibb & Sons Inc Antibiotic compositions and their preparation
EP0388510A1 (fr) * 1989-03-18 1990-09-26 Hoechst Aktiengesellschaft Compositions pharmaceutiques et leur utilisation pour la prophylaxie ou le traitement des maladies infectieuses bactériennes
EP0711774A1 (fr) * 1994-11-10 1996-05-15 Hoechst Aktiengesellschaft Sels d'addition cristallin de céphem et procédé pour leur préparation
US6911411B2 (en) * 2001-11-21 2005-06-28 Polyfuel, Inc. Catalyst agglomerates for membrane electrode assemblies
US20030186957A1 (en) * 2001-11-30 2003-10-02 Blanchflower Simon E. Methods of treatment and formulations of cephalosporin
WO2004054538A1 (fr) * 2002-12-16 2004-07-01 Akzo Nobel N.V. Traitement de la mastite

Also Published As

Publication number Publication date
WO2007145656A2 (fr) 2007-12-21
US20080318919A1 (en) 2008-12-25
EP1945223A2 (fr) 2008-07-23
PT1945223E (pt) 2010-10-14
PL1945223T3 (pl) 2010-12-31
CA2626273A1 (fr) 2007-12-21
ES2346573T3 (es) 2010-10-18
ATE472996T1 (de) 2010-07-15
JP2009513665A (ja) 2009-04-02
WO2007145656A3 (fr) 2008-08-14
JP5322649B2 (ja) 2013-10-23
CA2626273C (fr) 2013-05-14
EP1945223B1 (fr) 2010-07-07

Similar Documents

Publication Publication Date Title
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
JO2778B1 (en) Certain vehicles, installations and methods
NO20092637L (no) Fremgangsmater for behandling
SG164368A1 (en) Treatment of cancer
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200716525A (en) Process for preparation of sulfamide derivatives
TW200734344A (en) Antibacterial agents
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
TW200738659A (en) Novel compounds
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
TW200716646A (en) (S)-N-methylnaltrexone
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
TW200716606A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
UA94749C2 (en) Benzimidazole modulators of vr1
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
WO2008030883A3 (fr) Traitement du cancer
TW200700064A (en) Novel compounds
SI1937669T1 (sl) Novi derivati benzopirana kot odpiralci kalijevega kanala
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
WO2007097981A3 (fr) Alpha carbolines et leurs utilisations
TW200716088A (en) Formulations and methods for treating amyloidosis
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
UA85701C2 (ru) Способ получения ингибиторов триптазы

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080326

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20080814

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/16 20060101AFI20080930BHEP

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20091026

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101AFI20091020BHEP

Ipc: A61K 31/545 20060101ALI20091020BHEP

17Q First examination report despatched

Effective date: 20091106

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602006015340

Country of ref document: DE

Date of ref document: 20100819

Kind code of ref document: P

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2346573

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100707

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E008892

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101007

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101107

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100707

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20110408

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006015340

Country of ref document: DE

Effective date: 20110408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101027

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230919

Year of fee payment: 18

Ref country code: IE

Payment date: 20230925

Year of fee payment: 18

Ref country code: GB

Payment date: 20230914

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230925

Year of fee payment: 18

Ref country code: PL

Payment date: 20230929

Year of fee payment: 18

Ref country code: FR

Payment date: 20230914

Year of fee payment: 18

Ref country code: BE

Payment date: 20230918

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231108

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231013

Year of fee payment: 18

Ref country code: RO

Payment date: 20231002

Year of fee payment: 18

Ref country code: IT

Payment date: 20231011

Year of fee payment: 18

Ref country code: HU

Payment date: 20231004

Year of fee payment: 18

Ref country code: DE

Payment date: 20230915

Year of fee payment: 18

Ref country code: AT

Payment date: 20230925

Year of fee payment: 18